Tag Archives: Echosens

Wegovy MASH Label Analysis; Ozempic Offered Through NovoCare

FDA recently approved Wegovy (2.4mg semaglutide; QW SC GLP-1RA; view label) for the treatment of noncirrhotic MASH in adults with moderate to advanced liver fibrosis (F2-F3 MASH; view press release). The accelerated approval is based on results from Part 1 of the ongoing Ph3 ESSENCE study (view publication; previous FENIX insight). Additionally, Echosens and Novo Nordisk announced they are advancing their partnership to increase awareness and early diagnosis of MASH (view press release). Below, FENIX has conducted a Wegovy label analysis, including a comparison with Madrigal’s Rezdiffra (resmetirom), the only other approved treatment for MASH.

This content is for Read Less members only.

Already a member? Log in here

Tandem to Integrate with Abbott’s Glucose-Ketone Sensor; Insulet iOS App Integrates with Dexcom; Ypsomed and CamDiab Expand mylife Loop iOS; BI/Echosens Expand Partnership in MASH; Altimmune Initiates New Ph2 Study in ALD

A series of cardiometabolic-related news items has been observed from Tandem Diabetes Care/Abbott, Insulet/Dexcom, Ypsomed/CamDiab, Boehringer Ingelheim/Echosens, and Altimmune. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo and Echosens Partnership to Increase NASH Awareness; GlucoTrack to Initiate First In-human Clinical Study for GlucoTrack 2.0

Two cardiometabolic-related news items have been observed: Novo Nordisk and Echosens announced a partnership to increase awareness and advance early diagnosis of NASH; and GlucoTrack, formerly known as Integrity Applications, provided development updates on its Gen 2 non-invasive glucose monitor (press release). Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.

Already a member? Log in here